TYSABRI Global Observational Program in Safety (TYGRIS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00477113 |
Recruitment Status :
Completed
First Posted : May 22, 2007
Last Update Posted : June 22, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Multiple Sclerosis |
Study Type : | Observational |
Actual Enrollment : | 2207 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | TYGRIS: TYSABRI® Global Observational Program in Safety |
Study Start Date : | January 2007 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | May 2015 |

- Number of participants with serious infections, malignancies, and other SAEs [ Time Frame: 5 years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Key Inclusion Criteria:
- MS patients in the US and Canada receiving TYSABRI under standard clinical care for less than or equal to 3 infusions are eligible to participate in TYGRIS.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00477113
United States, Missouri | |
There may be mulitple sites in this clinical trial. Contact United BioSource Corporation | |
Kansas City, Missouri, United States, 64111 |
Study Director: | Medical Director | Biogen |
Responsible Party: | Biogen |
ClinicalTrials.gov Identifier: | NCT00477113 |
Other Study ID Numbers: |
101MS402 |
First Posted: | May 22, 2007 Key Record Dates |
Last Update Posted: | June 22, 2015 |
Last Verified: | June 2015 |
natalizumab MS Tysabri Multiple Sclerosis TYGRIS |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |